Pricing Log in Create free account
Friday 6 November 2026 Export KRYS’s income statement to Excel — free account

Krystal Biotech, Inc.

KRYS Healthcare Biotechnology

Krystal Biotech, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $389.1 million, up 33.9% from fiscal 2024.

Revenue
+30.2%
EPS
−22.3%
Free cash flow
+137.8%

Quarter to September 2026, against a year earlier

301.84 1.59 +0.53%
Market cap
$8.9B
P/E
39.2×
Fwd P/E
45.7×
Dividend yield
—
F-score
7/9
Altman Z
39.03
Beneish M
−2.27
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Valuation Filings

Krystal Biotech, Inc. (KRYS) Revenue

Alert me on Revenue

Krystal Biotech, Inc.'s revenue for fiscal 2025 was $389.1M, up 33.9% from $290.5M in fiscal 2024. Over the twelve months to 30 September 2026 it was $470.0M. Krystal Biotech, Inc. ranks 40th of 390 Biotechnology companies by revenue.

Revenue, annual

Embed this chart

Annual newest first

Period Revenue Change
FY2025 $389.1M 33.94%
FY2024 $290.5M 473.02%
FY2023 $50.7M —

Quarterly newest first

Period Revenue Change
Sep 2026 $127.3M 6.81%
Jun 2026 $119.2M 2.46%
Mar 2026 $116.4M 8.64%
Dec 2025 $107.1M 9.51%
9 more quarters

Revenue against peers

Company Revenue
MDGL Madrigal Pharmaceuticals, Inc. compare $1.4B
CAI Caris Life Sciences,�Inc. compare $1.0B
TGTX TG Therapeutics, Inc. compare $799.5M
KRYS Krystal Biotech, Inc. $470.0M
TWST Twist Bioscience Corporation compare $431.8M
PTGX Protagonist Therapeutics, Inc. compare $282.0M
IBRX ImmunityBio, Inc. compare $165.8M
CYTK Cytokinetics, Incorporated compare $113.3M
SYRE Spyre Therapeutics, Inc. compare $1.1M

What Revenue is

Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.

Reported line item

The full definition of Revenue →

More on KRYS